Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Efficacy and Safety of Anti-angiogenic Therapy With Intravenous Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous Malformations

NCT06264531 is registered in ClinicalTrials.gov with Fondation Ophtalmologique Adolphe de Rothschild as lead sponsor.

NCT NCT06264531
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06264531 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Efficacy and Safety of Anti-angiogenic Therapy With Intravenous Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous Malformations
Lead sponsor
Fondation Ophtalmologique Adolphe de Rothschild
Phase
Phase 2/3
Overall status
Recruiting
Start date
January 16, 2026
Completion date
January 15, 2029
Enrollment
54 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cerebral av malformation